Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Viktor Háda"'
Publikováno v:
ARKIVOC, Vol 2004, Iss 7, Pp 223-242 (2004)
Externí odkaz:
https://doaj.org/article/0045a687b69843c68008ec5a92800061
Publikováno v:
Letters in Drug Design & Discovery. 16:1248-1257
Background: Aryl-methoxybenzaldehydes substituted in various positions may serve as valuable starting materials for the synthesis of biologically active compounds. Methods: Biaryl-methoxybenzaldehydes and pyridyl-aryl-methoxybenzaldehydes were synthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3093fbd3b49229ba62b9b8c6f6898881
https://doi.org/10.2174/1570180816666181106123809
https://doi.org/10.2174/1570180816666181106123809
Autor:
Merle Nebel, Viktor Háda, Zoltán Urbányi, Tamás Schäfer, Róbert Kiss, Helga Hevér, Tanja Stadie, Piroska Kovács, Sonja Klingelhöfer
Publikováno v:
Biodrugs
Background In January 2017, the European Commission approved Terrosa® (company code RGB-10) as one of the first biosimilar medicinal products of teriparatide for the same indications as for the reference medicinal product Forsteo® (Lilly France S.A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb0e2858936d7fa8366cf39f43df655
https://doi.org/10.1007/s40259-019-00386-x
https://doi.org/10.1007/s40259-019-00386-x
Autor:
Antony Memboeuf, László Drahos, Viktor Háda, Tibor András Rokob, Lilla Turiák, Dany Jeanne Dit Fouque, Dániel Hüse, Károly Vékey, Ágnes Révész
Publikováno v:
Analytical Chemistry
Analytical Chemistry, American Chemical Society, 2019, 91 (20), pp.13128-13135. ⟨10.1021/acs.analchem.9b03362⟩
Analytical Chemistry, American Chemical Society, 2019, 91 (20), pp.13128-13135. ⟨10.1021/acs.analchem.9b03362⟩
International audience; Rigorous validation of amino acid sequence is fundamental in the characterization of original and biosimilar protein biopharmaceuticals. Widely accepted workflows are based on bottom-up mass spectrometry, and they often requir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b2f90cb5153131f330aa49715d3442
https://doi.org/10.1021/acs.analchem.9b03362
https://doi.org/10.1021/acs.analchem.9b03362
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 161:214-238
The extensive analytical characterization of protein biotherapeutics, especially of biosimilars, is a critical part of the product development and registration. High-resolution mass spectrometry became the primary analytical tool used for the structu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5609da41828ecd271e6d61996d59e83f
https://doi.org/10.1016/j.jpba.2018.08.024
https://doi.org/10.1016/j.jpba.2018.08.024
Autor:
Andrea Német-Hanzelik, Zsófia Dubrovay, György Keglevich, István Greiner, Hedvig Bölcskei, Viktor Háda
Publikováno v:
Letters in Drug Design & Discovery. 14:233-239
The benzyloxy-benzyl moiety is a valuable building block in medicinal chemistry, e.g. in case of the voltage gated sodium channel blockers Safinamide and Ralfinamide. To prepare further derivatives a series of (iodobenzyl)oxybenzaldehydes (3a-3i) use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b663be153950adcf68d414d5dd7e968c
https://doi.org/10.2174/1570180813666160804142245
https://doi.org/10.2174/1570180813666160804142245
Autor:
András Keglevich, Zita Hegedüs, László Hazai, Zoltán Bánóczi, Ildikò Szabò, József Tóvári, Péter Keglevich, Áron Szigetvári, Zsófia Lengyel, Csaba Szántay, Zsófia Dubrovay, Ivan Ranđelović, Ferenc Hudecz, Viktor Háda, Fruzsina L. Regenbach, Álmos Gorka-Kereskényi
Publikováno v:
Journal of peptide science : an official publication of the European Peptide Society. 24(10)
Some Vinca alkaloids (eg, vinblastine, vincristine) have been widely used as antitumor drugs for a long time. Unfortunately, vindoline, a main alkaloid component of Catharanthus roseus (L.) G. Don, itself, has no antitumor activity. In our novel rese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d485d69ff6f0e98a4c01723c762206
https://pubmed.ncbi.nlm.nih.gov/30084214
https://pubmed.ncbi.nlm.nih.gov/30084214
Autor:
Katalin Fónagy, Krisztina Gál, Sándor Farkas, György M. Keserű, Ildikó Magdó, Bela Kiss, Gábor Wágner, Katalin Nogradi, Zsolt Szombathelyi, Sándor Kolok, Viktor Háda, János Kóti, Amrita Ágnes Bobok, Istvan Gyertyan, István Greiner, György Domány
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:3845-3849
An HTS campaign of our corporate compound library resulted in thieno[2,3-b]pyridines derivative hits with mGluR5 negative allosteric modulator effects. During the hit-to-lead development our objective was to improve affinity, and to keep the ligand e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e17c5b02fdae6f3e4eeebfbae763785
https://doi.org/10.1016/j.bmcl.2014.06.057
https://doi.org/10.1016/j.bmcl.2014.06.057
Autor:
Viktor Háda, Zsófia Dubrovay, Janos Galambos, Zoltán Gulyás, Csaba Szántay, Antal Aranyi, Ágnes Lakó-Futó
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 84:309-322
In the course of exploring the possibilities of developing a new, improved process at Gedeon Richter for the production of the "bisindole" alkaloids vinblastine (VLB) and vincristine (VCR), some novel VLB/VCR-related trace impurities were detected by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc2c9b0fc6efaf2cf09617c6f151ecb
https://doi.org/10.1016/j.jpba.2012.09.008
https://doi.org/10.1016/j.jpba.2012.09.008
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. :183-189
Herein we discuss the structure elucidation of a labile estradiol-related degradant, X1. X1 was detected at Gedeon Richter as an unknown trace impurity in a pharmaceutical formulation containing estradiol (1a) and norethisterone acetate (NA) as activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13fd7ea9dcf59eca062a4647988d862
https://doi.org/10.1016/j.jpba.2013.02.015
https://doi.org/10.1016/j.jpba.2013.02.015